Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Walter H, Koch"'
Autor:
Daniel A. Haber, Mehmet Toner, Shyamala Maheswaran, Ravi Kapur, Shannon L. Stott, Jeffrey A. Engelman, John R. Walsh, Thomas A. Barber, Bruce E. Johnson, Wen Wei, Helena A. Yu, Martin Fleisher, Uma Giri, Hai T. Tran, Andrew Webb, Alona Muzikansky, Robert Maher, Douglas B. Fox, James P. Sullivan, Walter H. Koch, Pasi A. Jänne, Gregory J. Riely, John V. Heymach, Lecia V. Sequist, Tilak K. Sundaresan
Supplementary tables S1-S3. Supplementary Table S1: Institutional Tumor Genotyping Strategies. Supplementary Table S2: T790M Genotype by Modality. Supplementary Table S3: EGFR Primary Mutation Detection.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::872af2d4534314744579a6b80c0fd5be
https://doi.org/10.1158/1078-0432.22457103.v1
https://doi.org/10.1158/1078-0432.22457103.v1
Autor:
Daniel A. Haber, Mehmet Toner, Shyamala Maheswaran, Ravi Kapur, Shannon L. Stott, Jeffrey A. Engelman, John R. Walsh, Thomas A. Barber, Bruce E. Johnson, Wen Wei, Helena A. Yu, Martin Fleisher, Uma Giri, Hai T. Tran, Andrew Webb, Alona Muzikansky, Robert Maher, Douglas B. Fox, James P. Sullivan, Walter H. Koch, Pasi A. Jänne, Gregory J. Riely, John V. Heymach, Lecia V. Sequist, Tilak K. Sundaresan
Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine kinase inhibitors (TKI). As third-generation EGFR TKIs that overcome T790M-associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::045e97714a002cfa707153c4c4fce05c
https://doi.org/10.1158/1078-0432.c.6523506
https://doi.org/10.1158/1078-0432.c.6523506
Publikováno v:
BioTechniques, Vol 39, Iss 4S, Pp S557-S582 (2005)
Nearly 15 years have passed since the possibility of analyzing nucleic acid analytes in a massively parallel fashion was proposed using the then new concept of microarrays. A decade ago, proof of principle demonstration projects established the use o
Externí odkaz:
https://doaj.org/article/60fdb5e10cb742b498eb2428df9b658f
Autor:
Martin Fleisher, Walter H. Koch, Pasi A. Jänne, Jeffrey A. Engelman, Shyamala Maheswaran, Alona Muzikansky, Helena A. Yu, Bruce E. Johnson, Andrew Webb, Mehmet Toner, Gregory J. Riely, Daniel A. Haber, James P. Sullivan, John V. Heymach, Wen Wei, Ravi Kapur, Tilak K. Sundaresan, Uma Giri, Robert C. Maher, Douglas B. Fox, Hai T. Tran, John R. Walsh, Tom Barber, Lecia V. Sequist, Shannon L. Stott
Publikováno v:
Clinical Cancer Research. 22:1103-1110
Purpose: The T790M gatekeeper mutation in the EGFR is acquired by some EGFR-mutant non–small cell lung cancers (NSCLC) as they become resistant to selective tyrosine kinase inhibitors (TKI). As third-generation EGFR TKIs that overcome T790M-associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df1441111f3dcd7770bc591a8409b527
https://doi.org/10.1158/1078-0432.ccr-15-1031
https://doi.org/10.1158/1078-0432.ccr-15-1031
Publikováno v:
New Biotechnology. 29:682-688
Oncology drug development is a long and costly process associated with a success rate of 5-10%. The parallel development of companion diagnostic tests that will identify patients most likely to receive benefit has the potential to increase the succes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c10b522a23e831ea72467d80a61c83d5
https://doi.org/10.1016/j.nbt.2012.02.002
https://doi.org/10.1016/j.nbt.2012.02.002
Autor:
Love Py, Hinman Lm, Huang Sm, Walter H. Koch, Pennello G, Hackett J, Webster C, Torres-Cabassa A
Publikováno v:
The Pharmacogenomics Journal. 6:375-380
At the Washington DC Pharmacogenomics in Drug Development and Regulatory Decision-Making: Workshop III - Three Years of Promise, Proposals and Progress on Optimizing the Benefit/Risk of Medicines (11-13 April 2005), one break-out session (Track 2) fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0b18a82cb8efbd2011f2ce648e01176
https://doi.org/10.1038/sj.tpj.6500392
https://doi.org/10.1038/sj.tpj.6500392
Autor:
Joe Hackett, Kathleen F. Kerr, Garry Miyada, Leming Shi, Kathy Y Lee, Paul K. Wolber, Michael J. Fero, Timothy J Sendera, Walter H. Koch, Steven R. Bauer, Chitra Manohar, Rosalie K. Elespuru, James C. Fuscoe, Raymond R. Samaha, Richard P. Beyer, Michael A Wilson, Zora Modrusan, Patrick Gilles, Bud Bromley, Renata Zadro, Carole Foy, Laura H. Reid, Jesus Soriano, Robert Setterquist, Marc L. Salit, Federico Goodsaid, Elizabeth A. Wagar, Helen C. Causton, Shawn C. Baker, Z. Lewis Liu, Tamma Kaysser-Kranich, Richard Shippy, Richard D. Hockett, Chunmei Liu, Janet A. Warrington, David Gerhold, Helen Parkes, Gretchen L. Kiser, James D. Brenton, Ernest S. Kawasaki, Uwe Scherf, Pranvera Ikonomi, Frederike Wilmer, Xu Guo, Xiaolian Gao, Michael P Conley, Rafael A. Irizarry, Raj K. Puri, Anne Bergstrom Lucas, John Burrill, Thomas B. Ryder, Xiaoning Wu, Mickey Williams
Publikováno v:
Nature Methods. 2:731-734
Standard controls and best practice guidelines advance acceptance of data from research, preclinical and clinical laboratories by providing a means for evaluating data quality. The External RNA Controls Consortium (ERCC) is developing commonly agreed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddd904f40d6ffe928f575694a74c11ec
https://doi.org/10.1038/nmeth1005-731
https://doi.org/10.1038/nmeth1005-731
Autor:
Keith A. Candiotti, David M. Andrews, Fani Nhuch, David A. Lubarsky, Lin Wu, Aimee Kamat, David J. Birnbach, D. Michele Nikoloff, Walter H. Koch
Publikováno v:
Anesthesiology. 102:543-549
Background Some patients treated with ondansetron for postoperative nausea and vomiting do not respond to therapy. One possible mechanism for this failure is ultrarapid drug metabolism via the cytochrome P-450 system, specifically the enzyme 2D6 (CYP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50f6c7fb68ee56ec68a2c3f6599acdee
https://doi.org/10.1097/00000542-200503000-00011
https://doi.org/10.1097/00000542-200503000-00011
Autor:
Walter H. Koch, Maureen Fairchild, Run-Mei Pan, Jose de Leon, Margaret T. Susce, Peter J. Wedlund
Publikováno v:
The Journal of Clinical Psychiatry. 66:15-27
Objective: The cytochrome P450 2D6 (CYP2D6) enzyme metabolizes risperidone. CYP2D6 poor metabolizers have no CYP2D6 activity (7% of whites and 1%-2% of other races). This study tested whether the CYP2D6 poor metabolizer phenotype was associated with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52711a9232bc9adbc0b0feaa1961e8c2
https://doi.org/10.4088/jcp.v66n0103
https://doi.org/10.4088/jcp.v66n0103
Autor:
Peter J. Wedlund, Maureen Fairchild, Jose de Leon, Doris Robbins-Weilert, Walter H. Koch, Thomas B. Ryder, Clotilde Perbost, Weiwei Liu, Feng-Xiang Yan, Wen-Hwei Chou
Publikováno v:
Clinical Chemistry. 49:542-551
Background: There have been no published reports comparing the CYP450 GeneChip® microarray assay with more standard methods of genetic testing. Methods: We collected 20-mL blood samples from 236 volunteers for DNA isolation and testing before each i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b96cbbe61cb4f8f66cd43d2a7598b97
https://doi.org/10.1373/49.4.542
https://doi.org/10.1373/49.4.542